| Company Name: |
Borenpharm Co., Ltd
|
| Tel: |
027-65563561 |
| Email: |
sales@borenpharm.com |
| Products Intro: |
Product Name:Amino-PEG5-t-butyl acetate
CAS:2231845-67-1
Purity:95% HPLC Package:1g; 5g Remarks:0.8g
|
|
| | Amino-PEG5-t-butyl acetate Basic information |
| Product Name: | Amino-PEG5-t-butyl acetate | | Synonyms: | Amino-PEG5-t-butyl acetate;3,6,9,12,15-Pentaoxaheptadecanoic acid,17-amino-, 1,1-dimethylethyl ester;H2N-PEG5-CH2COOtBu;NH2-PEG5-C1-Boc;NH2-PEG5-CH2COOtBu;tert-butyl 17-amino-3,6,9,12,15-pentaoxaheptadecanoate;H2N-PEG5-CH2COOtBu/3,6,9,12,15-Pentaoxaheptadecanoic acid, 17-amino-, 1,1-dimethylethyl ester;Amino-PEG5-CH2COOtBu | | CAS: | 2231845-67-1 | | MF: | C16H33NO7 | | MW: | 351.44 | | EINECS: | | | Product Categories: | | | Mol File: | 2231845-67-1.mol |  |
| | Amino-PEG5-t-butyl acetate Chemical Properties |
| | Amino-PEG5-t-butyl acetate Usage And Synthesis |
| Biological Activity | NH2-PEG5-C1-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. | | References | [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 |
| | Amino-PEG5-t-butyl acetate Preparation Products And Raw materials |
|